A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and y tetanus toxoid conjugate vaccine in children aged 2-10 y

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 12, 2012, Pages 1882-1891

  Vesikari, Timo ^a   Forstén, Aino ^a   Boutriau, Dominique ^b   Bianco, Véronique ^b   Van Der Wielen, Marie ^b   Miller, Jacqueline M ^c  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b GSK   (Belgium)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Bactericidal activity; Child; Conjugate vaccine; Immunogenicity; Persistence; Polysaccharide vaccine; Safety; Tetravalent meningococcal vaccine

Indexed keywords

BACTERIAL VACCINE; BACTERIUM ANTIBODY; MENINGOCOCCUS TETANUS TOXOID CONJUGATE VACCINE; MENINGOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANOREXIA; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHILD; CONTROLLED STUDY; DOSE RESPONSE; DROWSINESS; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; FOLLOW UP; HEMATOMA; HUMAN; HUMAN EXPERIMENT; HYPERGLYCEMIA; IMMUNOGENICITY; INFECTION PREVENTION; IRRITABILITY; LARYNGITIS; MALE; MENINGOCOCCOSIS; MULTICENTER STUDY; NEISSERIA MENINGITIDIS; NORMAL HUMAN; OTITIS MEDIA; PAIN; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCHOOL CHILD; SERUM BACTERICIDAL ACTIVITY; SIDE EFFECT; SINGLE DRUG DOSE; SKIN REDNESS; SWELLING; TESTIS TORSION; TETANUS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VACCINATION REACTION;

BACTERICIDAL ACTIVITY; CHILD; CONJUGATE VACCINE; IMMUNOGENICITY; PERSISTENCE; POLYSACCHARIDE VACCINE; SAFETY; TETRAVALENT MENINGOCOCCAL VACCINE;

ANIMALS; ANTIBODIES, BACTERIAL; BLOOD BACTERICIDAL ACTIVITY; CHILD; CHILD, PRESCHOOL; COMPLEMENT SYSTEM PROTEINS; FEMALE; FINLAND; HUMANS; MALE; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; TIME FACTORS;

EID: 84871183978     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.22165     Document Type: Article

References (43)

1. Harrison LH, Pass MA, Mendelsohn AB, Egri M, Rosenstein NE, Bustamante A, et al. Invasive meningococcal disease in adolescents and young adults. JAMA 2001; 286:694-9; PMID:11495619; http://dx.doi.org/10.1001/jama.286.6.694.
2. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27(Suppl 2):B51-63; PMID:19477562; http://dx.doi.org/10. 1016/j.vaccine.2009.04.063
3. Khatami A, Pollard AJ. The epidemiology of meningococcal disease and the impact of vaccines. Expert Rev Vaccines 2010; 9:285-98; PMID:20218857; http://dx.doi.org/10.1586/erv.10.3.
4. European Centre for Disease Prevention and Control. Annual epidemiological report. Reporting on 2009 surveillance data and 2010 epidemic intelligence data. Stockholm ECDC 2011; 155-57.
5. Trotter CL, Chandra M, Cano R, Larrauri A, Ramsay ME, Brehony C, et al. A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev 2007; 31:27-36; PMID:17168995; http://dx.doi.org/10.1111/j.1574-6976.2006.00060. x.
6. European Centre for Disease Prevention and Control (ECDC). Surveillance of invasive disease in Europe 2008/09. Available at: http://ecdc.europa.eu/en/ publications/Publications/1107-SUR-IBD-2008-09.pdf [Accessed 10/08/2012].
7. Kriz P, Wieffer H, Holl K, Rosenlund M, Budhia S, Vyse A. Changing epidemiology of meningococcal disease in Europe from the mid-20th to the early 21st Century. Expert Rev Vaccines 2011; 10:1477-86; PMID:21988310; http://dx.doi.org/10.1586/erv.11.117.
8. Thulin HS, Toros B, Fredlund H, Olcen P, Molling P. Genetic characterisation of the emerging invasive Neisseria meningitidis serogroup Y in Sweden, 2000 to 2010. Euro Surveill 2011; 16.
9. Bidmos FA, Neal KR, Oldfield NJ, Turner DP, Ala'Aldeen DA, Bayliss CD. Persistence, replacement, and rapid clonal expansion of meningococcal carriage isolates in a 2008 university student cohort. J Clin Microbiol 2011; 49:506-12; PMID:21123536; http://dx.doi.org/10.1128/JCM.01322-10.
10. The European Meningococcal Disease Society (EMGM). 11th EMGM meeting, May 18-20, 2011, Ljubljana, Slovenia. Emergence of serogroup Y: Poster abstracts P035-P40.
11. Pollard AJ. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J 2004; 23(Suppl):S274-9; PMID:15597069.
12. Harrison LH. Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev 2006; 19:142-64; PMID:16418528; http://dx.doi.org/10.1128/ CMR.19.1.142-164.2006.
13. Bröker M, Veitch K. Quadrivalent meningococcal vaccines: hyporesponsiveness as an important consideration when choosing between the use of conjugate vaccine or polysaccharide vaccine. Travel Med Infect Dis 2010; 8:47-50; PMID:20188306; http://dx.doi.org/10.1016/j.tmaid.2009.12.001.
14. Maiden MC, Ibarz-Pavón AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008; 197:737-43; PMID:18271745; http://dx.doi.org/10.1086/527401.
15. Pichichero ME. Meningococcal conjugate vaccines. Expert Opin Biol Ther 2005; 5:1475-89; PMID:16255651; http://dx.doi.org/10.1517/14712598.5.11.1475.
16. Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003; 326:365-6; PMID:12586669; http://dx.doi.org/10.1136/bmj.326. 7385.365.
17. Borrow R, Miller E. Long-term protection in children with meningococcal C conjugate vaccination: lessons learned. Expert Rev Vaccines 2006; 5:851-7; PMID:17184222; http://dx.doi.org/10.1586/14760584.5.6.851.
18. Campbell H, Andrews N, Borrow R, Trotter C, Miller E. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 2010; 17:840-7; PMID:20219881; http://dx.doi.org/10.1128/CVI.00529-09.
19. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364:365-7; PMID:15276396; http://dx.doi.org/10.1016/S0140-6736(04) 16725-1.
20. de Voer RM, Mollema L, Schepp RM, de Greeff SC, van Gageldonk PG, de Melker HE, et al. Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine. PLoS ONE 2010; 5:e12144; PMID:20730091; http://dx.doi.org/10.1371/ journal.pone.0012144.
21. Larrauri A, Cano R, García M, Mateo S. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 2005; 23:4097-100; PMID:15908059; http://dx.doi.org/10.1016/j.vaccine.2005.03. 045.
22. Keyserling H, Papa T, Koranyi K, Ryall R, Bassily E, Bybel MJ, et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med 2005; 159:907-13; PMID:16203934; http://dx.doi.org/10.1001/archpedi.159.10.907.
23. Jackson LA, Baxter R, Reisinger K, Karsten A, Shah J, Bedell L, et al.; V59P13 Study Group. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin Infect Dis 2009; 49:e1-10; PMID:19476428; http://dx.doi.org/10.1086/599117.
24. Pichichero M, Casey J, Blatter M, Rothstein E, Ryall R, Bybel M, et al. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children. Pediatr Infect Dis J 2005; 24:57-62; PMID:15665711; http://dx.doi.org/10.1097/01.inf. 0000148928.10057.86.
25. Black S, Klein NP, Shah J, Bedell L, Karsten A, Dull PM. Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age. Vaccine 2010; 28:657-63; PMID:19895922; http://dx.doi.org/10.1016/j.vaccine.2009.10.104.
26. Marc LaForce F, Ravenscroft N, Djingarey M, Viviani S. Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine 2009; 27(Suppl 2):B13-9; PMID:19477559; http://dx.doi.org/10.1016/j.vaccine.2009.04.062.
27. Lee CH, Kuo WC, Beri S, Kapre S, Joshi JS, Bouveret N, et al. Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa. Vaccine 2009; 27:726-32; PMID:19063929; http://dx.doi.org/10. 1016/j.vaccine.2008.11.065.
28. Sow SO, Okoko BJ, Diallo A, Viviani S, Borrow R, Carlone G, et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 2011; 364:2293-304; PMID:21675889; http://dx.doi.org/10.1056/ NEJMoa1003812.
29. Kshirsagar N, Mur N, Thatte U, Gogtay N, Viviani S, Préziosi M-P, et al. Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine 2007; 25(Suppl 1):A101-7; PMID:17532101; http://dx.doi.org/10.1016/j.vaccine.2007.04.050.
30. Baxter R, Baine Y, Ensor K, Bianco V, Friedland LR, Miller JM. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age. Pediatr Infect Dis J 2011; 30:e41-8; PMID:21200360; http://dx.doi.org/10.1097/INF.0b013e3182054ab9.
31. Bermal N, Huang L-M, Dubey AP, Jain H, Bavdekar A, Lin T-Y, et al. Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults. Hum Vaccin 2011; 7:239-47; PMID:21343698; http://dx.doi.org/10.4161/hv.7.2.14068.
32. Knuf M, Kieninger-Baum D, Habermehl P, Muttonen P, Maurer H, Vink P, et al. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine 2010; 28:744-53; PMID:19887137; http://dx.doi.org/10.1016/j. vaccine.2009.10.064.
33. Memish ZA, Dbaibo G, Montellano M, Verghese VP, Jain H, Dubey AP, et al. Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile. Pediatr Infect Dis J 2011; 30:e56-62; PMID:21278617; http://dx.doi.org/10.1097/ INF.0b013e31820e6e02.
34. Östergaard L, Lebacq E, Poolman J, Maechler G, Boutriau D. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine 2009; 27:161-8; PMID:18834910; http://dx.doi.org/10.1016/j.vaccine.2008.08.075.
35. Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U, Tichmann-Schumann I, Maurer H, Maurer L, et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children. Vaccine 2011; 29:4264-73; PMID:21420417; http://dx.doi.org/10.1016/j.vaccine.2011.03.009.
36. Vesikari T, Karvonen A, Bianco V, Van der Wielen M, Miller J. Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial. Vaccine 2011; 29:4274-84; PMID:21443965; http://dx.doi.org/10.1016/j.vaccine. 2011.03.043.
37. Bilukha OO, Rosenstein N; National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005; 54(RR-7):1-21; PMID:15917737.
38. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969; 129:1307-26; PMID:4977280; http://dx.doi.org/10.1084/jem.129.6.1307.
39. Richmond P, Goldblatt D, Fusco PC, Fusco JD, Heron I, Clark S, et al. Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults. Vaccine 1999; 18:641-6; PMID:10547423; http://dx.doi.org/10.1016/S0264-410X(99)00276-5.
40. Maslanka SE, Gheesling LL, Libutti DE, Donaldson KB, Harakeh HS, Dykes JK, et al.; The Multilaboratory Study Group. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin Diagn Lab Immunol 1997; 4:156-67; PMID:9067649.
41. Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection - serum bactericidal antibody activity. Vaccine 2005; 23:2222-7; PMID:15755600; http://dx.doi.org/10.1016/j.vaccine.2005.01.051.
42. Centers for Disease Control and Prevention (CDC). Inadvertent misadministration of meningococcal conjugate vaccine - United States, June-August 2005. MMWR Morb Mortal Wkly Rep 2006; 55:1016-7; PMID:16988640.
43. Amanna IJ, Messaoudi I, Slifka MK. Protective immunity following vaccination: how is it defined? Hum Vaccin 2008; 4:316-9; PMID:18398296; http://dx.doi.org/10.4161/hv.4.4.5751.